Americans are unlikely to see generic versions of semaglutide — the active ingredient in Novo Nordisk’s Ozempic and Wegovy — until at least the end of 2031, according to a May 13 NBC News report. Novo Nordisk first applied for…
GLP-1s
An analysis of more than 430,000 patients found metabolic and bariatric surgery results in 20 percentage-point greater weight loss than GLP-1 receptor agonist use, according to an article in the April issue of Surgery for Obesity and Related Diseases. Results…
Roughly half of the clients served by CVS Health’s pharmacy benefit manager cover GLP-1s, company leadership said May 6 on a quarterly earnings call. CVS Caremark, CVS’ PBM, serves employers and healthcare payers more broadly. Executive Vice President and Group…
As oral GLP-1 therapies draw increasing attention, most pharmacy leaders say they are not making major operational changes yet. However, they are closely monitoring how a potential shift could reshape distribution, reimbursement and pharmacy strategy. Rather than prompting immediate action,…
Since the Wegovy pill entered the U.S. market in early January, clinicians have written more than 2 million prescriptions for the weight loss GLP-1 pill, according to Novo Nordisk’s first-quarter financial results published May 6. The launch might have been…
Advertisement
The first phase of the GLP-1 boom was defined by shortages and brand-name manufacturers sparring with compounding pharmacies. The next phase will be marked by Medicare coverage expansions and new GLP-1 pills for weight loss — two developments expected to…
As retailers, payers and drugmakers expand access to GLP-1 therapies — with companies like Amazon and Walmart launching weight management programs — the drug class is reshaping both care delivery and pharmaceutical investment strategies. That demand is influencing drug development,…
Boston-based Beth Israel Deaconess Medical Center researchers have found GLP-1 drugs were associated with fewer peptic ulcer diagnoses among patients with Type 2 diabetes. The study, published in Clinical Gastroenterology and Hepatology, analyzed EHR data from more than 66,000 adults…
The FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, the latest move in a monthslong crackdown on the compounded GLP-1 market. The 503B bulks list identifies bulk drug substances outsourcing facilities can use in compounding…
Semaglutide was linked to a higher risk of a rare eye condition, nonarteritic anterior ischemic optic neuropathy, compared to another class of diabetes drugs. The study, published Feb. 12 in JAMA Ophthalmology, examined 102,361 veterans, including 11,478 who initiated semaglutide…